KROS
Keros Therapeutics, Inc.
Biotechnology
Market Cap$433M
5Y Perf.-59.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
KROS vs KRYS vs RARE vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
KRYS
Krystal Biotech, Inc.
Biotechnology
Market Cap$8.75B
5Y Perf.+477.1%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
KROS vs KRYS vs RARE vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KROS | KRYS | RARE | FOLD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $433M | $8.75B | $2.57B | $4.55B |
| Revenue (TTM) | $244M | $417M | $669M | $634M |
| Net Income (TTM) | $87M | $225M | $-609M | $-27M |
| Gross Margin | 99.5% | 92.8% | 83.6% | 87.9% |
| Operating Margin | 28.9% | 42.8% | -83.9% | 5.2% |
| Forward P/E | 5.1x | 39.3x | — | 40.6x |
| Total Debt | $17M | $9M | $1.28B | $483M |
| Cash & Equiv. | $287M | $496M | $434M | $214M |
KROS vs KRYS vs RARE vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KROS
KRYS
RARE
FOLD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Keros Therapeutics,… (KROS) | 100 | 40.5 | -59.5% |
| Krystal Biotech, In… (KRYS) | 100 | 577.1 | +477.1% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KROS vs KRYS vs RARE vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KROS and KRYS are tied at the top with 2 categories each — the right choice depends on your priorities. Krystal Biotech, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. FOLD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
KROS
Keros Therapeutics, Inc.
The Growth Play
KROS has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 67.7%, EPS growth 146.0%
- Lower volatility, beta 1.03, Low D/E 5.6%, current ratio 15.45x
- Beta 1.03, current ratio 15.45x
- 67.7% revenue growth vs FOLD's 20.0%
Best for: growth exposure and sleep-well-at-night
KRYS
Krystal Biotech, Inc.
The Long-Run Compounder
KRYS is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 26.9% 10Y total return vs FOLD's 119.2%
- 53.9% margin vs RARE's -91.0%
- 17.6% ROA vs RARE's -45.8%, ROIC 18.0% vs -89.4%
Best for: long-term compounding
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the clearest fit if your priority is income & stability.
- beta 0.63
- Beta 0.63 vs RARE's 1.42
- +137.9% vs RARE's -21.8%
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KROS | 67.7% revenue growth vs FOLD's 20.0% |
| Value | KROS | Lower P/E (5.1x vs 40.6x) |
| Quality / Margins | KRYS | 53.9% margin vs RARE's -91.0% |
| Stability / Safety | FOLD | Beta 0.63 vs RARE's 1.42 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +137.9% vs RARE's -21.8% |
| Efficiency (ROA) | KRYS | 17.6% ROA vs RARE's -45.8%, ROIC 18.0% vs -89.4% |
KROS vs KRYS vs RARE vs FOLD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
Segment breakdown not available.
KROS vs KRYS vs RARE vs FOLD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKRYSLAGGINGRARE
Who Leads Where
KRYS leads in 3 of 6 categories
KROS leads 1 • FOLD leads 1 • RARE leads 0
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
FOLDAmicus Therapeutics, …
1leads
KROSKeros Therapeutics, I…
1leads
KRYSKrystal Biotech, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs KROSvs FOLDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KRYS4/6
Valuation MetricsMultiples, price ratios, and targets
KROS4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KRYS6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
KRYS5/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KRYS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 2.7x KROS's $244M. KRYS is the more profitable business, keeping 53.9% of every revenue dollar as net income compared to RARE's -91.0%. On growth, KRYS holds the edge at +31.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KROSKeros Therapeutic… | KRYSKrystal Biotech, … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $244M | $417M | $669M | $634M |
| EBITDAEarnings before interest/tax | $72M | $185M | -$536M | $40M |
| Net IncomeAfter-tax profit | $87M | $225M | -$609M | -$27M |
| Free Cash FlowCash after capex | $106M | $237M | -$487M | $30M |
| Gross MarginGross profit ÷ Revenue | +99.5% | +92.8% | +83.6% | +87.9% |
| Operating MarginEBIT ÷ Revenue | +28.9% | +42.8% | -83.9% | +5.2% |
| Net MarginNet income ÷ Revenue | +35.7% | +53.9% | -91.0% | -4.3% |
| FCF MarginFCF ÷ Revenue | +43.4% | +56.9% | -72.8% | +4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -87.3% | +31.9% | -2.4% | +23.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +66.7% | +52.5% | -17.2% | -89.0% |
KRYS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
KROS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 5.1x trailing earnings, KROS trades at a 88% valuation discount to KRYS's 43.4x P/E. On an enterprise value basis, KROS's 2.3x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | KROSKeros Therapeutic… | KRYSKrystal Biotech, … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $433M | $8.7B | $2.6B | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $163M | $8.3B | $3.4B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | 5.06x | 43.38x | -4.48x | -164.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 39.33x | — | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 2.26x | 49.21x | — | 114.88x |
| Price / SalesMarket cap ÷ Revenue | 1.78x | 22.48x | 3.82x | 7.17x |
| Price / BookPrice ÷ Book value/share | 1.45x | 7.29x | — | 16.29x |
| Price / FCFMarket cap ÷ FCF | 4.09x | 46.30x | — | 152.43x |
KROS leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
KRYS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
KRYS delivers a 19.3% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $-6 for RARE. KRYS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), KROS scores 5/9 vs FOLD's 4/9, reflecting solid financial health.
| Metric | KROSKeros Therapeutic… | KRYSKrystal Biotech, … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +14.3% | +19.3% | -6.1% | -12.0% |
| ROA (TTM)Return on assets | +13.3% | +17.6% | -45.8% | -3.2% |
| ROICReturn on invested capital | +167.9% | +18.0% | -89.4% | +5.3% |
| ROCEReturn on capital employed | +15.6% | +14.8% | -46.4% | +5.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.01x | — | 1.76x |
| Net DebtTotal debt minus cash | -$271M | -$487M | $842M | $269M |
| Cash & Equiv.Liquid assets | $287M | $496M | $434M | $214M |
| Total DebtShort + long-term debt | $17M | $9M | $1.3B | $483M |
| Interest CoverageEBIT ÷ Interest expense | — | — | -14.49x | 1.00x |
KRYS leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
KRYS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KRYS five years ago would be worth $41,919 today (with dividends reinvested), compared to $2,192 for KROS. Over the past 12 months, FOLD leads with a +137.9% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors KRYS at 50.1% vs KROS's -35.4% — a key indicator of consistent wealth creation.
| Metric | KROSKeros Therapeutic… | KRYSKrystal Biotech, … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -37.2% | +20.2% | +10.7% | +1.5% |
| 1-Year ReturnPast 12 months | -15.1% | +116.9% | -21.8% | +137.9% |
| 3-Year ReturnCumulative with dividends | -73.0% | +238.5% | -44.5% | +19.0% |
| 5-Year ReturnCumulative with dividends | -78.1% | +319.2% | -77.2% | +48.6% |
| 10-Year ReturnCumulative with dividends | -42.0% | +2688.5% | -59.4% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -35.4% | +50.1% | -17.8% | +6.0% |
KRYS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs KROS's 51.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KROSKeros Therapeutic… | KRYSKrystal Biotech, … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.03x | 1.12x | 1.42x | 0.63x |
| 52-Week HighHighest price in past year | $22.55 | $303.00 | $42.37 | $14.50 |
| 52-Week LowLowest price in past year | $10.41 | $122.80 | $18.29 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +51.6% | +97.9% | +61.7% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 64.3 | 66.6 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 409K | 264K | 1.8M | 3.0M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: KROS as "Buy", KRYS as "Buy", RARE as "Buy", FOLD as "Buy". Consensus price targets imply 781.4% upside for KROS (target: $103) vs 0.1% for FOLD (target: $15).
| Metric | KROSKeros Therapeutic… | KRYSKrystal Biotech, … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $102.60 | $332.75 | $51.50 | $14.50 |
| # AnalystsCovering analysts | 16 | 17 | 33 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +86.6% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KRYS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KROS leads in 1 (Valuation Metrics).
Best OverallKrystal Biotech, Inc. (KRYS)Leads 3 of 6 categories
Loading custom metrics...
KROS vs KRYS vs RARE vs FOLD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KROS or KRYS or RARE or FOLD a better buy right now?
For growth investors, Keros Therapeutics, Inc.
(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Keros Therapeutics, Inc. (KROS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KROS or KRYS or RARE or FOLD?
On trailing P/E, Keros Therapeutics, Inc.
(KROS) is the cheapest at 5. 1x versus Krystal Biotech, Inc. at 43. 4x. On forward P/E, Krystal Biotech, Inc. is actually cheaper at 39. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — KROS or KRYS or RARE or FOLD?
Over the past 5 years, Krystal Biotech, Inc.
(KRYS) delivered a total return of +319. 2%, compared to -78. 1% for Keros Therapeutics, Inc. (KROS). Over 10 years, the gap is even starker: KRYS returned +26. 9% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KROS or KRYS or RARE or FOLD?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 125% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — KROS or KRYS or RARE or FOLD?
By revenue growth (latest reported year), Keros Therapeutics, Inc.
(KROS) is pulling ahead at 67. 7% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KROS or KRYS or RARE or FOLD?
Krystal Biotech, Inc.
(KRYS) is the more profitable company, earning 52. 6% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KROS or KRYS or RARE or FOLD more undervalued right now?
On forward earnings alone, Krystal Biotech, Inc.
(KRYS) trades at 39. 3x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 1. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KROS: 781. 4% to $102. 60.
08Which pays a better dividend — KROS or KRYS or RARE or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is KROS or KRYS or RARE or FOLD better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KROS and KRYS and RARE and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(KROS: -87.3% · KRYS: 31.9%)Net Margin>
%
(KROS: 35.7% · KRYS: 53.9%)P/E Ratio<
x
(KROS: 5.1x · KRYS: 43.4x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.